ReviewInternational journal of nanomedicine2025
Nanotechnology-Driven Strategies in Osteosarcoma Advances in Treatment: Immunotherapy and Drug Delivery.
Review in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- A 'three-axis synergy' immunotherapeutic strategy for malignant bone tumors based on natural bioactives and bioactive materials.Bioactive materials · 2026Review
- Decoding osteosarcoma mechanobiology: PIEZO channels in tumor progression, immune remodeling, and pain.Cancer metastasis reviews · 2026Review
- Nanoparticle-based mechanistic and multifunctional strategies for targeted osteosarcoma therapy.Discover nano · 2026Review
- Cyclo-(His-Phe) Complexes with Copper and Zinc Nanoparticles Have Antimicrobial Properties and Targeted Anticancer Potential Against Osteosarcoma Cells.Biomolecules · 2026Article
- From Bench to Bedside: Advancements in Precision Oncology and Drug Discovery for Osteosarcoma.Cancers · 2026Review
- Engineering immunity in osteosarcoma: nanomedicine strategies for overcoming immune evasion.Frontiers in immunology · 2026Review
- AI-enabled photoresponsive nanoplatforms for coordinated osteosarcoma therapy and bone regeneration.Frontiers in bioengineering and biotechnology · 2026Article
- Exploiting B7-H3: Molecular Insights and Immunotherapeutic Strategies for Osteosarcoma.Bioengineering (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteosarcoma (OS), the most prevalent primary malignant bone tumor, exhibits highly aggressive and metastatic potential, accounting approximately 56% of all primary malignant bone malignancies. While neoadjuvant chemotherapy with surgery remains standard, challenges persist: suboptimal margins, non-specific drug biodistribution, and systemic toxicity. Nanomaterial engineering offers transformative multifunctional platforms, integrating biomimetic targeting, stimuli-responsive release, and theranostics to enhance tumor penetration and reduce off-target effects. Immunotherapy combats OS by activating antitumor immunity, reprogramming the immunosuppressive tumor microenvironment (TME), and synergizing with checkpoint inhibitors/cell therapies. Ligand-functionalized nanocarriers significantly improve chemotherapeutic bioavailability and targeting. This review systematically explores the dual role of nanoplatforms in osteosarcoma therapeutics: (1) immunotherapy via TME reprogramming and (2) precision oncology through advanced drug delivery paradigms, providing critical insights into their translational potential for overcoming current therapeutic bottlenecks and ultimately improving clinical outcomes for OS patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.